The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy.
The cGAS-STING signaling in cardiovascular and metabolic diseases: Future novel target option for pharmacotherapy.
复制标题
心血管和代谢疾病中的cGAS-STING信号:未来药物治疗的新靶点选择
DOI:
10.1016/j.apsb.2021.05.011
复制
发表时间:
2022-01
期刊:
影响因子:
--
通讯作者:
Wang Q
中科院分区:
文献类型:
--
作者:
Oduro PK;Zheng X;Wei J;Yang Y;Wang Y;Zhang H;Liu E;Gao X;Du M;Wang Q
The cyclic GMP–AMP synthase (cGAS)–stimulator of interferon genes (STING) signaling exert essential regulatory function in microbial-and onco-immunology through the induction of cytokines, primarily type I interferons. Recently, the aberrant and deranged signaling of the cGAS–STING axis is closely implicated in multiple sterile inflammatory diseases, including heart failure, myocardial infarction, cardiac hypertrophy, nonalcoholic fatty liver diseases, aortic aneurysm and dissection, obesity, etc. This is because of the massive loads of damage-associated molecular patterns (mitochondrial DNA, DNA in extracellular vesicles) liberated from recurrent injury to metabolic cellular organelles and tissues, which are sensed by the pathway. Also, the cGAS–STING pathway crosstalk with essential intracellular homeostasis processes like apoptosis, autophagy, and regulate cellular metabolism. Targeting derailed STING signaling has become necessary for chronic inflammatory diseases. Meanwhile, excessive type I interferons signaling impact on cardiovascular and metabolic health remain entirely elusive. In this review, we summarize the intimate connection between the cGAS–STING pathway and cardiovascular and metabolic disorders. We also discuss some potential small molecule inhibitors for the pathway. This review provides insight to stimulate interest in and support future research into understanding this signaling axis in cardiovascular and metabolic tissues and diseases. The review summarizes the current impact of hyperactivation of the cGAS–STING signaling, with emphasis on the link with cardiovascular and metabolic diseases and the emerged pathway's inhibitors for therapeutic prospects.
登录
查看更多内容
影响因子:
64.8
作者:
通讯作者:
--
影响因子:
4.8
作者:
Chen, Hai-Yan;Pang, Xiao-Yu;Xu, Hua-Guo
通讯作者:
Xu, Hua-Guo
影响因子:
11.4
作者:
Cavlar, Taner;Deimling, Tobias;Hornung, Veit
通讯作者:
Hornung, Veit
影响因子:
64.5
作者:
Barnett, Katherine C.;Coronas-Serna, Julia M.;Kagan, Jonathan C.
通讯作者:
Kagan, Jonathan C.
影响因子:
4.4
作者:
Chen, Honghe;Pei, Rongjuan;Chen, Xinwen
通讯作者:
Chen, Xinwen